Tuesday, October 8, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Cardiovascular disease is still the leading cause of death in the United States, with 2022 setting a record for deaths due to cardiovascular disease in the US at close to 1 million. LDL-cholesterol is a major modifiable cardiovascular risk factor which continues to be poorly controlled and Lp(a) is a powerful, emerging risk factor that is under-recognized and under-appreciated.

The Family Heart Foundation is a non-profit organization dedicated to research, education, and advocacy and as part of our ongoing research efforts, we have examined the state of LDL-C control among 38M Americans at high and very high-risk for cardiovascular disease in the proprietary Family Heart Database. This session will provide an update on current LDL-C treatment guidelines, Lp(a) screening recommendations, and key findings and insights from an analysis of the Family Heart database.

Learning Objectives

• Individualize treatment of LDL-C to achieve more aggressive goals in patients with a history of ASCVD and increased risk for recurrent events, incorporating the latest data, clinical guidelines, and expert recommendations.
• Incorporate Lp(a) testing into routine risk evaluation to better define a patient's risk for future cardiovascular events.
• Take away potential solutions which could be implemented to improve awareness, treatment, and outcomes for people at high risk for cardiovascular disease.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.